Soooo. For all you speculators, thoughtless people and outright liars that are on this board here is the real story of the Canadian Cancer Patient. She has been taking Leronlimab since September 2020. She started on Leronlimab as part of a trial and when the trial ended she and her oncologist had to apply for the Canadian Special Access Program to stay on Leronlimab. If she was in the US the application would have been under Right to Try. The approval for the SAP was granted one month ago. She has been on Leronlimab for 14 months and she has been No Evidence of Disease - NED for exactly one year now. This is the first time Leronlimab has received this type of approval in Canada. This does potentially open the door for other cancer patients to apply under the same legislation as the first approval is definitely the hardest. It took Health Canada 6 weeks to make the decision. I know these are the facts because I know her personally.
This was posted by Spencer on YMB about 1 hour
Soooo. For all you speculators, thoughtless people and outright liars that are on this board here is the real story of the Canadian Cancer Patient. She has been taking Leronlimab since September 2020. She started on Leronlimab as part of a trial and when the trial ended she and her oncologist had to apply for the Canadian Special Access Program to stay on Leronlimab. If she was in the US the application would have been under Right to Try. The approval for the SAP was granted one month ago. She has been on Leronlimab for 14 months and she has been No Evidence of Disease - NED for exactly one year now. This is the first time Leronlimab has received this type of approval in Canada. This does potentially open the door for other cancer patients to apply under the same legislation as the first approval is definitely the hardest. It took Health Canada 6 weeks to make the decision. I know these are the facts because I know her personally.
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Heparin Market's Growth to Reach USD 9.68 Billion in Coming Years
Heparin Market Size and Growth Insights The heparin market is witnessing promising growth, projected to attain USD 9.68 billion by the end of 2032, from its current market size of USD 7.35 billion in 2023. This growth is largely attributable to the escalating prevalence of cardiovascular diseases and conditions like venous thromboembolism (VTE). The compound annual growth...
Continue Reading
Discover Apple Intelligence: Creative Tools and Enhanced Features
Unlock the Magic of Apple Intelligence Apple has taken a bold step forward with the unveiling of its latest update, showcasing the power of Apple Intelligence. With the rollout of iOS 18.2, iPadOS 18.2, and macOS Sequoia 15.2, users can dive into an array of new features designed to enhance their Apple experience. This exciting update introduces tools that not only...
Continue Reading
Diversified Energy Company Finalizes Maverick Acquisition Deal
Diversified Energy Company Completes Significant Acquisition Diversified Energy Company PLC (DEC), an independent energy leader focused on natural gas and liquids, has made a notable stride in enhancing its market presence. The company recently finalized its acquisition of Maverick Natural Resources, an endeavor highlighted in previous announcements. Details of the...
Continue Reading
Glen Burnie Bancorp Shows Growth in Latest Earnings Report
Glen Burnie Bancorp Reports Third Quarter Growth Glen Burnie Bancorp, known for its strong community banking focus, reported noteworthy financial results for its latest third quarter. This period has showcased various enhancements in performance metrics, positioning the organization favorably within the competitive landscape of banking. Financial Highlights Net Income and...
Continue Reading
Navient Announces Exciting Q4 2025 Dividend for Shareholders
Navient's Fourth Quarter Dividend Announcement Navient (NASDAQ: NAVI), a leading provider in student loan services, has made headlines with the announcement of its fourth quarter dividend for 2025. The company's board of directors has approved a dividend of $0.16 per share on its common stock. Details of the Dividend This dividend declaration is a testament to Navient's...
Continue Reading